g0 FY2018 Annual Report Figure 4
Figure 4. Casein kinase II (CKII) phosphorylates DNA topoisomerase II (topo II), thus activating the ATPase domain of the enzyme (left). This activation cancels the effects of anti-cancer drug ICRF-193. If CKII activity is attenuated (right), the efficacy of ICRF-193 is rescued. The G0 Cell Unit demonstrated this mechanism in fission yeast, a simple model that could be used for anti-cancer drug screening.
Date:
28 February 2024
Copyright OIST (Okinawa Institute of Science and Technology Graduate University, 沖縄科学技術大学院大学). Creative Commons Attribution 4.0 International License (CC BY 4.0).
Share on:
